Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04387734 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Ocrevus in Relapsing Multiple Sclerosis

Study acronym: MOBILE-RMS
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Apr 30, 2026 to Sep 30, 2026v15
  2. Study completion pushed from Feb 28, 2026 to Apr 30, 2026v14
  3. Study completion date: Dec 30, 2025 to Feb 28, 2026v13
  4. Study completion date: Sep 2025 to Dec 30, 2025v12
  5. Primary completion date changed from estimate of Jan 2025 to Feb 17, 2025v11
Show 9 earlier versionsHide 9 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v10
  2. Primary completion date: Sep 2023 to Jan 2025v9
  3. 2 versions Re-verified since Sep 14, 2021, no change to tracked fieldsv7-v8
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2021 to Feb 5, 2021
    • Eligibility criteria shortened, about 174 words
    • Site details revised at 2 of 2 sites
    v6
  5. Start date: Dec 2020 to Feb 2021
    • Eligibility criteria shortened, about 1 word
    v5
  6. Start date: Oct 2020 to Dec 2020v4
  7. Re-verified, no change to tracked fieldsv3
  8. Secondary endpoints: details revised at 2 of 13 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can improve ambulatory functions after one-year treatment with Ocrevus in comparison with other Disease Modifying Treatments (DMT). Sixty qualified individuals with RMS will be evenly assigned into two groups: Ocrevus and other DMT. Each group will receive the respective treatment following the FDA regulations over the one-year course. Their ambulatory functions will be assessed five times three months apart. In addition, they will receive brain MRI scans three times six months apart. Their ambulatory functions and MRI measurements will be compared between groups over time to fulfill the purposes of this study.
Trial Details
NCT Number NCT04387734
Lead Sponsor Georgia State University
Collaborators: Multiple Sclerosis Center of Atlanta
Conditions
(from sponsor)		 Relapsing Multiple Sclerosis
Related terms Multiple Sclerosis
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov